New and Noteworthy

79
The current basic science study evaluates the utility of cardiac biomarkers and echocardiography 80 using tissue velocity imaging and strain rate imaging for the early detection of Bevacizumab and 81 Sunitinib mediated cardiotoxicity. 
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Introduction 145
Cardio-Oncology is a novel discipline that focuses on the prevention, diagnosis, and 146 management of cancer patients who are at risk of developing cardiovascular complications as a 147 result of their anti-cancer treatment. Despite the beneficial effects of chemotherapy agents in 148 increasing overall survival of cancer patients, cardiotoxicity remains a serious complication of 149 many systemic anti-cancer therapies. (4, 5, 26, 32, 36, 47, 49, 58) The treatment strategy for each 150 patient is individualized, involving a combination of surgical intervention, radiation, 151 chemotherapy, and novel targeted biological therapy. is approved for the treatment of metastatic CRC by decreasing tumor progression and improving 161 overall survival. (22, 29) Additionally, solid tumors including RCC are dependent on the 162 development and expansion of a vascular network to support their growth. As opposed to BVZ 163 which inhibits only VEGF-A and its interaction with VEGFR, SNT is an oral tyrosine kinase 164 inhibitor approved for the treatment of metastatic RCC, that blocks the activity of multiple 165 receptors, including VEGFR 1-3, platelet-derived growth factor receptors (PDGFR) α and β, and 166 AMPK. (10, 21, 26) Despite the beneficial effects of both BVZ and SNT in improving overallsurvival in the CRC and RCC populations, an unexpected side effect of both anti-cancer drugs is 168 the risk of developing cardiotoxicity in nearly 1 in 4 individuals. (6, 10, 24, 47, 50, 58) 169
In clinical practice, serial monitoring of cardiac biomarkers and left ventricular ejection 170 fraction (LVEF) using non-invasive cardiac imaging are important diagnostic tools in the 171 detection of cardiac dysfunction amongst cancer patients. (3, 7, 8, 14, 15, 35, 52) In the last 172 decade, the use of cardiac biomarkers, including Troponin-I (TnI), C-reactive protein (CRP), and 173 brain natriuretic peptide (BNP) have emerged as a more sensitive and specific tool for the early 174 identification, assessment, and monitoring of cardiotoxicity due to anti-cancer drugs. (1, 7, 8, 34, 175 35, 42, 52) Recent studies have demonstrated that frequent sampling of TnI and CRP was able to 176 identify a subset of women with breast cancer at high risk of Doxorubicin and Trastuzumab 177 (DOX+TRZ) mediated cardiac dysfunction prior to a decrease in LVEF. (7, 44) Whether these 178 cardiac biomarkers, including high sensitivity troponins, (37) can similarly detect early evidence 179 of BVZ and SNT mediated cardiac dysfunction, requires further study. 180
Non-invasive assessment of LVEF using multiple-gated acquisition scintigraphy and 181 transthoracic echocardiography (TTE) continue to be the most common methods for monitoring 182 cardiac dysfunction in the cancer setting. (3, 13-16, 44, 51, 54) Despite the established use of 183 LVEF as a measure of cardiac function, compensatory myocardial reserve enables adequate 184 ventricular output in the presence of dysfunctional cardiomyocytes, such that the extent of 185 cardiac injury is often not recognized and/or underestimated at an early time point in treatment. 186 (14) Therefore, novel echocardiographic parameters including tissue velocity imaging (TVI) and 187 strain rate imaging (SRI) have been developed to improve the diagnostic value of non-invasive 188 echocardiography. (13, 14, 16, 28, 44, 51, 59 ) A number of basic science and clinical studies 189 have confirmed the role of TVI and SRI for the early detection of DOX+TRZ mediated cardiac 190 dysfunction in the breast cancer setting. (13, 14, 16, 30, 44, 51) However, little is known aboutwhether these novel echocardiographic parameters can be applied in the early detection of BVZ 192 or SNT mediated cardiotoxicity. 193
The objective of this study is to evaluate whether cardiac biomarkers and/or novel 194 echocardiographic techniques can detect early manifestations of cardiac dysfunction before a 195 reduction in LVEF is identified, in a murine model of BVZ and SNT induced cardiomyopathy. 
Murine echocardiography 236
Echocardiographic data was collected using a 13-MHz probe (Vivid 7, version 11.2, GE 237
Medical Systems, Milwaukee, WI, US) with TVI capability. All 75 C57Bl/6 mice were awake 238 and underwent TTE at baseline and were followed daily thereafter for 14 days, as previously 239 described. (2, 30, 40, 41, 55, 56, 60) Each mouse was imaged in the parasternal long axis and 240 short axis windows, in addition to acquisition of 3 different frames of M-mode echocardiography 241 for the non-invasive determination of LV morphology and function. (2, 30, 40, 41, 55, 56, 60 ) 242 LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), and posterior wall 243 thickness (PWT) were measured. Left ventricular ejection fraction (LVEF) was calculated by 244 measurement of LV end-systolic and end-diastolic volumes using the prolate ellipsoid geometric 245 model. (57) Endocardial velocity (V endo ) was calculated using TVI, which was acquired in the 246 short axis window at the level of the papillary muscles, at a rate of 483 frames/s. (30, 46, 55, 60 ) 247
For peak V endo , a region of interest (0.2 x 0.2 mm) was manually positioned along the posterior 248 wall of the endocardium. Radial SR was measured over an axial distance of 1 mm (width, 0.6 249 mm) and the temporal smoothing filters were turned off for all measurements. (30, 46, 55, 60 ) 250
Post-processing of all images was conducted offline using the EchoPAC PC software (Vivid 7, 251 version 11.2, GE Medical Systems, Milwaukee, WI, US). The echocardiographic observers were 252 blinded to the various treatment groups. 253
To assess the variability of V endo and radial SR, a total of 30 mice were randomly chosen 254 from the various treatment groups. Both V endo and radial SR measurements were performed 255 independently by a single observer (D.S.J.), two weeks apart, to determine intra-observer 256 variability. Inter-observer variability was determined from echocardiographic measurements that 257 were processed separately by two independent observers (K.A.B. and D.S.J.). 258
Hemodynamics 260
Non-invasive measurements of heart rate (HR) and blood pressure (BP) were performed 261 in all 75 conscious, restrained mice via a tail cuff method (CODA system, High Throughput, 262
Kent Scientific, Torrington, CT), as previously described. (2, 17) Briefly, the holding platform 263 was heated to 30°C, at which time 5 BP readings were recorded with 1 minute rest intervals 264 between readings. At baseline, day 7, and day 14, BP measurements were collected, from which 265 average values for mean arterial pressure (MAP) were calculated. 266
Cardiac biomarkers: hsTnI 267
Blood was collected via the internal jugular vein in all 75 animals at baseline, day 7, and 268 day 10. Upon euthanasia at day 14, the heart was removed and all blood remaining in the 269 thoracic cavity was immediately collected through pipette. Serum high sensitivity troponin I 270 (hsTnI) was quantified using a mouse-specific enzyme-linked immunosorbent assays (Life 271 Diagnositics, Inc. Cat. No. 2010-1-HS) and the absorbance was read at 450 nm using a 272 microplate reader (MRX Microplate Reader, Dynex Technologies Inc. 1CXD-4588, Chantilly, 273
VA, US). 274
Histological Analysis 275
A total of 35 mice (n=5 controls; n=15 for BVZ; and n=15 for SNT) were euthanized at 276 day 8 and day 14 for electron microscopy (EM) studies. After the chest cavity was rapidly 277 opened and the major blood vessels and connective tissue were removed, the heart was blotted 278 dry, weighed, and the heart weight/body weight ratio was calculated. Half of the LV was 279 sectioned for histological analysis via EM, as previously described. (30, 55, 60) Samples were 280 dehydrated in ascending concentrations of ethanol and embedded in Epon 812 using standard 281 techniques. Thin sections were stained with uranyl acetate and lead citrate, viewed, andphotographed on a Philips CM12 electron microscope to determine the extent of cell 283 degradation. 284
Oxolipidomic analysis 285
A total of 35 mice (n=5 controls; n=15 for BVZ; and n=15 for SNT) were euthanized at 286 day 8 and day 14 for oxidized phosphatidylcholine (OxPC) studies. OxPC, a marker of 287 inflammation and oxidative stress (OS), was quantified using liquid chromatography and 288 electrospray ionization tandem mass spectrometry. (20) formic acid with a flow rate of mobile phase at 0.260 mL/min. The time program used was 0.01 296 minute 32% B; 1.50 minutes 32% B; 4.00 minutes 45% B; 5.00 minutes 52% B; 8.00 minutes 297 58% B; 11.00 minutes 66% B; 14.00 minutes 70% B; 18.00 minutes 75% B; 21.00 minutes 97% 298 B; 25.00 minutes 97% B; 25.10 minutes 32% B, and 30.00 minutes 32% B. The elution was 299 stopped at 30.10 minutes. Auto-oxidized 16:0-18:2 phosphatidylcholine and 16:0-20:4 300 phosphatidylcholine were used to generate an assigned theoretical structure corresponding to the 301 molecular weight. Oxidation products were separated from nonoxidized phosphatidylcholine 302 allowing for correct determination of OxPC molecules in samples. Data were collected using 303 Analyst 1.6 software (Applied Biosystems, Ontario, Canada) and quantified using MultiQuant 304 2.1 (Absciex, Ontario, Canada). 305
Protein analysis: Apoptotic markers 307
A total of 65 mice (n=5 controls; n=20 for Doxorubicin (DOX); n=20 for BVZ; and n=20 308 for SNT) were used for Western analysis of apoptotic markers at day 14. Mice treated with a 309 single i.p. injection of DOX (20 mg/kg) were used as a positive control for increased cardiac 310 apoptosis, as previously described (30, 60). Frozen heart tissue was ground in liquid nitrogen and 311 proteins were extracted in the radioimmunoprecipition buffer containing protease and 312 phosphatase inhibitors (Thermo Scientific). A total of 30 μg of protein was loaded and 313 electrophoresed in 12% sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) and 314 transferred to a polyvinylidene fluoride membrane (Roche Diagnostics). (30, 38, 39, 55, 60 ) 315
Membranes were incubated with the primary antibody to Caspase-3, Bax, and PARP (Cell 316
Signaling) overnight at 4°C. Anti-rabbit (Cell Signaling) secondary antibody was used to detect 317 the primary antibody and was accomplished using the ECL Plus detection reagent (Western 318
Lightning Plus-ECL, Amersham). For the loading control, a polyclonal antibody to GAPDH 319 (Sigma) was used. Band intensities were quantified using image analysis software (Quantity 320
One; BioRad Laboratories, Inc). (30, 38, 39, 55, 60 ) 321
Statistical Analysis 322
All data are expressed as mean±SD. Statistical significance between echocardiographic 323 measurements was determined using a 1 (Genotype) x 2 (Time) mixed factorial design with 324 repeated measures on the time factor. For post-hoc analysis, repeated measures of ANOVA were 325 used to evaluate for significance between independent factors. In post-hoc between group 326 analysis, Levene's test was used to check for homogeneity of group variances. P-values for main 327 effects and interactions were also recorded where appropriate. Histological analyses involved 328 non-parametric comparison of scores, ranging from 1-4 was calculated using the Kruskal-Wallis Heart rate, LV cavity dimensions, and systolic function were similar at baseline between 370 all treatment groups. In mice receiving either BVZ or SNT, there were no overt visible 371 behavioral changes nor weight loss during the 14 day study. Heart weight/body weight ratio, 372 heart rate, and PWT remained within normal limits throughout the duration of the 14-day study 373 for all treatment groups (Table 1 ). In both BVZ and SNT treated mice, conventional 374 echocardiographic indices showed a significant increase in LVEDD and a decrease in LVEF 375 beginning at day 13 (Figures 1-2) . At day 13, in the BVZ treatment group, LVEDD initially 376 increased from 3.1±0.2mm at baseline to 3.9±0.2mm at day 14. Similarly, in the SNT treatment 377 group, LVEDD increased from 3.1±0.2mm at baseline to 3.9±0.3mm at day 14 ( Figure 1 , Table  378 1). Both BVZ and SNT treatment groups demonstrated a decrease in conventional LVEF by day 379 13 of the study (Figure 2) . 380
Both BVZ and SNT treatment groups demonstrated normal V endo and SR values at 381 baseline. TVI parameters, including V endo and SR, decreased at day 8 in both BVZ and SNT 382 treatment groups (Figures 3-4) . In mice treated with BVZ, V endo decreased from 3.5±0.3cm/s at 383 baseline to 2.4±0.1cm/s as early as day 8, and continued to decrease to 1.3±0.1cm/s at day 14. at day 14 (Figures 3-4) . Similarly, in SNT treated mice, V endo decreased from 3.4±0.2cm/s 386 at baseline to 2.5±0.2cm/s at day 8, and continued to decrease to a final value of 1.2±0.2cm/s at 387 day 14. In addition, radial SR decreased from 21±2s at day 14 (Figures 3-4) .
The intra-and inter-observer agreement rates for V endo were 0.1±0.05cm/s and 390 0.2±0.05cm/s, respectively. The intra-and inter-observer agreement rates for SR were 0.8±0.4s 115±6 at day 7, to 135±4 mmHg at day 14 (p<0.05) ( Figure 5) . 400
Cardiac biomarkers: hsTnI 401
All mice demonstrated non-detectable hsTnI values at baseline, day 7, and day 10. In 402 animals treated with either BVZ or SNT, the hsTnI levels increased to 1.8±0.3 ng/ml and 2.3±0.4 403 ng/ml (p<0.05) respectively, at day 14 (Table 2) . 404
Electron microscopy 405
Approximately 15,000 cells were scanned from 3 randomly derived blocks of myocardial 406 tissue and evaluated for dilation of the sarcoplasmic reticulum and loss of cell integrity. At day 8, 407
there was no evidence of cellular injury in mice treated with BVZ or SNT as compared to 408 controls. However, at day 14, BVZ and SNT treated animals demonstrated an increased loss of 409 cellular integrity and myofibril disarray (Figure 6 ). There was no statistical difference, however, 410 between the BVZ and SNT treatment groups at day 14. 411
Oxidative stress and apoptotic markers
A total of 82 distinct OxPC studies were evaluated in each experimental group at days 8 413 and 14. There was no discernable change in OxPC in mice treated with either BVZ or SNT at 414 day 8 as compared to controls. At day 14, however, the heat map generated for the most 415 abundant OxPC molecular demonstrated a 10-fold increase in OxPC molecules in mice treated 416 with either BVZ or SNT as compared to controls (Figures 7A and B) . Western blot analysis 417 demonstrated evidence of apoptotic cell death and Caspase-3 cleavage amongst BVZ and SNT 418 treated animals at day 14 (p<0.05) (Figure 8 ). Mice treated with either BVZ or SNT 419 demonstrated 2.5-fold and 2-fold increases in Caspase-3 levels, respectively (p<0.05). As 420 compared to saline treated animals, there was no significant evidence of an increase in either Bax 421 or PARP expression at day 14 in mice treated with BVZ or SNT (data not shown). overall morbidity and mortality, these novel anti-cancer drugs are associated with an increased 439 risk of developing cardiotoxicity. (6, 11, 18, 22, 24, 25, 43, 45, 50, 53, 61) The aim of the current 440 study was to determine the utility of cardiac biomarkers and TVI parameters for the early 441 detection of BVZ and SNT mediated cardiotoxicity, potentially avoiding the development of 442 advanced heart failure. In a murine model of BVZ and SNT mediated cardiac dysfunction, we 443 demonstrated: i) development of systemic hypertension; ii) serial hsTnI was unable to detect 444 early myocardial dysfunction; iii) TVI and SRI parameters were able to detect LV systolic 445 dysfunction 5 days earlier than traditional LVEF parameters; and iv) evidence of loss of cellular 446 integrity with increased OS and apoptosis. 447
BVZ and SNT mediated hypertension 448
The use of novel anti-angiogenic drugs including BVZ and SNT result in the 449 development of systemic hypertension as outlined in several basic science and clinical studies. 450 (10, 12, 18, 31, 43, 45, 50, 53) Both agents inhibit the VEGF pathway, which causes down-451 regulation of endothelial nitric oxide (NO) synthase expression and decreased synthesis of 452 endothelial NO. This results in systemic vasculature constriction and development of 453 hypertension. (27, 31, 48) In an acute murine model using Swiss-Webster male mice, Chu et al. 454 observed no change in blood pressure over a 12-day period among animals administered SNT. 455 (12) Similarly, in our current 458 study, C57Bl/6 male mice treated with either BVZ or SNT developed an increase in MAP as 459 early as day 7, which continued to increase at day 14 by nearly 50% as compared to baseline. 460
Although increased LV wall thickness is often associated with increased afterload, our study 461 demonstrated no change in LV wall dimensions throughout the study. This may be due to the 462 acute nature of our 14 day model, as hypertrophy is not typically observed until 4 to 6 weeks 463 following the onset of hypertension. (2) Additionally, as there was no overall change in heart 464 weight/body weight ratio in mice treated with either BVZ or SNT, it is plausible that these two 465 anti-cancer drugs may interfere with the adaptive cardiac hypertrophy that occurs in the setting 466 of increased afterload. Therefore, future animal studies are warranted to elucidate the subsequent 467 hemodynamic side effects of chronic administration of BVZ and SNT in a murine model. cardiac dysfunction, we previously demonstrated that although LVEF decreased at day 5, TVI 501 was significantly decreased in both V cndo and radial SR as early as 24 hours following treatment. 502 (30) However, the role of TVI for the early detection of BVZ and SNT induced cardiotoxicity in 503 an animal model has not been previously explored. In the current study, mice treated with BVZ 504 or SNT demonstrated an increase in LV cavity dimensions and a decrease in conventional echoparameters, including LVEF, at day 13. In contrast, V endo and radial SR decreased 5 days earlier 506 in mice receiving either BVZ or SNT, confirming that TVI is a sensitive and reproducible 507 measure of early cardiac dysfunction. We hypothesize as BVZ and SNT both interrupt the VEGF 508 pathway, (9, 11, 19, 21, 23, 43, 61) this common feature may explain why there was a similar 509 decline in cardiac function at the same time point. Considering the lower variability of these 510 novel imaging techniques, TVI may be a more feasible imaging modality for the early detection 511 of subclinical LV systolic dysfunction. However, these results require validation in the clinical 512 setting of CRC and RCC patients treated with BVZ and SNT, respectively. 513
Mechanisms of BVZ and SNT mediated cardiotoxicity 514
The precise underlying mechanisms of BVZ and SNT mediated cardiotoxicity have yet to 515 be fully elucidated. In an animal model of age-matched, wild-type Swiss-Webster mice treated 516 with 40 mg/kg/d of SNT, Chu et al. demonstrated mitochondrial swelling and degenerative 517 changes in cardiomyocytes using transmission electron microscopy at day 12. (11) Our EM 518 findings corroborate this previous study, as changes in cellular integrity do not occur early at day 519 8, but rather later at day 14. Additionally, in a chronic 6 month model involving mice treated 520 with BVZ 10 mg/kg i.v. every 2 weeks, there was evidence of increased cardiac fibrosis as 521 measured by hydroxyproline content, in comparison to control EndoCD/5-FC treatment groups. 522 (9) Our study validates the significant loss and disruption of cardiac myofibrils in BVZ and SNT 523 treated animals. These findings may be indicative of cellular damage caused by impaired ATP 524 generation due to mitochondrial dysfunction. An important finding from our current study is the 525 absence of cardiac fibrosis, suggesting that the dysfunction observed may be reversible. 526
Although BVZ inhibits VEGF-A alone and SNT inhibits multiple receptors including 527 VEGFR 1-3, PDGFR α and β, and AMPK, (10, 18, 21, 26) it is plausible that the cardiotoxic side 528 effects of these two different anti-cancer agents may result in the activation of commondownstream apoptotic and OS pathways. Although a few studies have previously evaluated the 530 relationship between SNT mediated cardiotoxicity and increased apoptosis, (11, 27) there is a 531 paucity of data on BVZ induced cardiac dysfunction and this pathway. Apoptosis occurs through 532 inhibition of AMPK signaling (primarily affected by SNT), which cause the JNK and p38 533 pathways to be activated, resulting in the enhanced expression of several pro-apoptotic genes, 534 such as Bax, caspases, and poly ADP ribose polymerase (PARP). (30, 38, 39, 55, 60) SNT mediated heart failure. 549
Limitations 550
There are a few limitations to our study. The current study characterized drug-induced 551 cardiac dysfunction in an acute murine model of BVZ and SNT mediated heart failure. As these 552 drugs are administered over a period of several months in patients with metastatic CRC or RCC,it would be useful to design a chronic murine model of BVZ and SNT mediated cardiac 554 dysfunction, to more closely mimic the clinical setting. Second, we exclusively evaluated 555 changes in cardiac hsTnI. In future studies, the evaluation of various cardiac biomarkers, 556 including cardiac hsTnT and NT pro-BNP should be investigated for their predictive role of 557 detecting early cardiac dysfunction. Finally, there may be significant gender-based differences in 558 the cardiotoxic side effects of BVZ and SNT. As the current study focused on C57Bl/6 male 559 mice, future studies evaluating BVZ and SNT-mediated cardiotoxicity in female mice are 560 All data are expressed as mean±SD. *p<0.05 between baseline and day 7 for BVZ; **p<0.05 847 between both baseline and day 7 as compared to day 14 for BVZ; #p<0.05 between baseline and 848 day 7 for SNT; ##p<0.05 between both baseline and day 7 as compared to day 14 for SNT. 
